Skip to main content

Entelos Raises $25M in Private Financing Round

NEW YORK, Sept. 6 – In silico drug discovery company Entelos of Menlo Park, Calif., said Thursday it had raised $25 million in a private placement.

Bear Stearns Health Innoventures led the series C round of financing, while Earlybird, Equity4life, and Compaq Computer also invested in the round. Previous investors, including Abingworth Ventures, Boulder Ventures, Brentwood Ventures, Charles River Ventures, and St. Paul Ventures, also reinvested in the company.

Entelos said it would use the proceeds from the financing to expand its business development efforts and to fund internal research and development programs.

Currently, Entelos has several partnerships with pharmaceutical companies to identify pathways, prioritize drug targets, and improve the drug development process.

The company has developed PhysioLab, a system designed to allow researchers to test experiments and hypotheses in silico, predicting the results through simulation. The system is available for asthma, obesity, diabetes, and adipocytes. 

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.